$17.20
1.36% yesterday
Nasdaq, Nov 25, 10:01 pm CET
ISIN
US0352551081
Symbol
ANIK
Sector
Industry

Anika Therapeutics, Inc. Target price 2024 - Analyst rating & recommendation

Anika Therapeutics, Inc. Classifications & Recommendation:

Buy
100%

Anika Therapeutics, Inc. Price Target

Target Price $26.50
Price $17.20
Potential
Number of Estimates 2
2 Analysts have issued a price target Anika Therapeutics, Inc. 2025 . The average Anika Therapeutics, Inc. target price is $26.50. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 2 analysts: 2 Analysts recommend Anika Therapeutics, Inc. to buy, 0 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Anika Therapeutics, Inc. stock has an average upside potential 2025 of . Most analysts recommend the Anika Therapeutics, Inc. stock at Purchase.

Sales and Margin forecast 2024, 2025 & 2026

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Revenue Million $ 166.66 150.20
6.67% 9.88%
EBITDA Margin 1.07% 11.20%
155.02% 942.79%
Net Margin -49.71% -25.72%
418.37% 48.26%

2 Analysts have issued a sales forecast Anika Therapeutics, Inc. 2024 . The average Anika Therapeutics, Inc. sales estimate is

$150m
Unlock
. This is
8.51% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$151m 7.90%
Unlock
, the lowest is
$149m 9.12%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 $167m 6.67%
2024
$150m 9.88%
Unlock
2025
$115m 23.77%
Unlock
2026
$124m 8.50%
Unlock

1 Analyst has issued an EBITDA forecast Anika Therapeutics, Inc. 2024 . The average Anika Therapeutics, Inc. EBITDA estimate is

$16.8m
Unlock
. This is
180.22% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$16.8m 180.22%
Unlock
, the lowest is
$16.8m 180.22%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2023 $1.8m 158.69%
2024
$16.8m 839.83%
Unlock
2025
$12.5m 25.74%
Unlock
2026
$15.2m 21.97%
Unlock

EBITDA Margin

2023 1.07% 155.02%
2024
11.20% 942.79%
Unlock
2025
10.91% 2.59%
Unlock
2026
12.27% 12.47%
Unlock

2 Anika Therapeutics, Inc. Analysts have issued a net profit forecast 2024. The average Anika Therapeutics, Inc. net profit estimate is

$-38.6m
Unlock
. This is
60.40% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-35.6m 63.55%
Unlock
, the lowest is
$-41.7m 57.23%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 $-82.9m 452.94%
2024
$-38.6m 53.37%
Unlock
2025
$-2.9m 92.39%
Unlock
2026
$5.1m 274.83%
Unlock

Net Margin

2023 -49.71% 418.37%
2024
-25.72% 48.26%
Unlock
2025
-2.57% 90.01%
Unlock
2026
4.14% 261.09%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 & 2026

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Earnings Per Share $ -5.64 -2.63
452.94% 53.37%
P/E negative
EV/Sales 1.45

2 Analysts have issued a Anika Therapeutics, Inc. forecast for earnings per share. The average Anika Therapeutics, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

$-2.63
Unlock
. This is
60.39% higher
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
$-2.42 63.55%
Unlock
, the lowest is
$-2.84 57.23%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 $-5.64 452.94%
2024
$-2.63 53.37%
Unlock
2025
$-0.20 92.40%
Unlock
2026
$0.35 275.00%
Unlock

P/E ratio

Current -2.59 79.53%
2024
-6.54 152.51%
Unlock
2025
-86.00 1,214.98%
Unlock
2026
49.14 157.14%
Unlock

Based on analysts' sales estimates for 2024, the Anika Therapeutics, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 1.32 20.00%
2024
1.45 9.48%
Unlock
2025
1.90 31.17%
Unlock
2026
1.75 7.84%
Unlock

P/S ratio

Current 1.53 19.34%
2024
1.68 9.30%
Unlock
2025
2.20 31.18%
Unlock
2026
2.03 7.84%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today